Yohimbine Use for Physical Enhancement and Its Potential Toxicity

REFERENCES

• Banna KM, Back SE, Do P, See RE. Yohimbine stress potentiates conditioned cue-induced reinstatement of heroin-seeking in rats. Behav Brain Res. 2010;208:144–148.
   PubMed Web of Science ®Google Scholar
• Berlan M, Galitzky J, Riviere D, Foureau M, Tran MA, Flores R, Louvet JP, Houin G, Lafontan M. Plasma catecholamine levels and lipid mobilization induced by yohimbine in obese and non-obese women. Int J Obes. 1991;15:305–315.
   PubMedGoogle Scholar
• Berlin I, Stalla-Bourdillon A, Thuillier Y, Turpin G, Puech AJ. Absence d'efficacité de la yohimbine dans le traitement de l'obesité. J Pharmacol. (Paris). 1986;17:343–347.
   PubMedGoogle Scholar
• Betz JM, White KD, der Marderosian AH. Gas chromatographic determination of yohimbine in commercial yohimbe products. J AOAC Inter. 1995;78:1189–1194.
   PubMed Web of Science ®Google Scholar
• Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Giffin SL. 2008 Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 26th annual report. Clin Toxicol. 2009;47:911–1084.
   PubMed Web of Science ®Google Scholar
• Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Giffin SL. 2009 Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 27th annual report. Clin Toxicol. 2010;48:979–1178.
   PubMed Web of Science ®Google Scholar
• Bronstein AC, Spyker DA, Cantilena LR Jr, Green J, Rumack BH, Heard SE. 2006 Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS). Clin Toxicol. 2007;45:815–917.
   PubMed Web of Science ®Google Scholar
• Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Heard SE. 2007 Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 25th annual report. Clin Toxicol. 2008;46:927–1057.
   PubMed Web of Science ®Google Scholar
• Charney DS, Heninger GR, Redmond DE. Yohimbine-induced anxiety and increased noradrenergic function in humans: effects of diazepam and clonidine. Life Sci. 1983;33:19–29.
   PubMed Web of Science ®Google Scholar
• Charney DS, Heninger GR, Sternberg DE. Assessment of α2-adrenergic autoreceptor function in humans: effects of oral yohimbine. Life Sci. 1982;30:2033–2041.
   PubMed Web of Science ®Google Scholar
• Crespi F. Anxiolytics antagonize yohimbine-induced central noradrenergic activity: a concomitant in vivo voltammetry-electrophysiology model of anxiety. J Neurosci Meth. 2009;180:97–105.
   PubMedGoogle Scholar
• Dunn RW, Corbett R. Yohimbine-induced seizures involve NMDA and GABAergic transmission. Neuropharmacology. 1992;31:389–395.
   PubMedGoogle Scholar
• Friesen K, Palatnick W, Tenenbein M. Benign course after massive ingestion of yohimbine. J Emerg Med. 1993;11:287–288.
   PubMedGoogle Scholar
• Galitzky J, Rivière D, Tran MA, Montastruc JL, Berlan M. Pharmacodynamic effects of chronic yohimbine treatment in healthy volunteers. Eur J Clin Pharmacol. 1990;39:447–451.
   PubMedGoogle Scholar
• Galitzky J, Taouis M, Berlan M, Rivière D, Garrigues M, Lafontan M. α2-antagonist compounds and lipid mobilization: evidence for a lipid mobilizing effect of oral yohimbine in healthy male volunteers. Eur J Clin Invest. 1988;18:587–594.
   PubMed Web of Science ®Google Scholar
• Garfield SL, Gershon S, Sletten I, Sundland DM, Ballou S. Chemically induced anxiety. Int J Neuropsych. 1967;3:426–433.
   Google Scholar
• Giampreti A, Lonati D, Locatelli C, Rocchi L, Campailla MT. Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol. 2009;47:827–829.
   Web of Science ®Google Scholar
• Grossman E, Rosenthal T, Peleg E, Holmes C, Goldstein DS. Oral yohimbine increases blood pressure and sympathetic nervous outflow in hypertensive patients. J Cardiovasc Pharmacol. 1993;22:22–26.
   PubMed Web of Science ®Google Scholar
• Grunewald KK, Bailey RS. Commercially marketed supplements for bodybuilding athletes. Sports Med. 1993;15:90–103.
   PubMed Web of Science ®Google Scholar
• Gurguis GN, Uhde TW. Plasma 3-methoxy-4-hydrocyphenylethylene glycol (MHPG) and growth hormone responses to yohimbine in panic disorder patients and normal controls. Psychoneuroendocrinology. 1990;15:217–224.
   PubMed Web of Science ®Google Scholar
• Halcomb HSE, Parab S, Ravikumar PR, Hoffman RS, Nelson LS. Massive yohimbine overdose associated with sodium channel blockade. Clin Toxicol. 2006;44:731.
   Web of Science ®Google Scholar
• Hameedi FA, Woods SW, Rosen MI, Pearsall HR, Kosten TR. Dose-dependent effects of yohimbine on methadone-maintained patients. Am J Drug Alcohol Abuse. 1997;23:327–333.
   PubMed Web of Science ®Google Scholar
• Hedner T, Edgar B, Edvinsson, Hedner J, Persson B, Pettersson A. Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers. Eur J Clin Pharmacol. 1992;43:651–656.
   PubMedGoogle Scholar
• Henauer SA, Gillespie HK, Hollister LE. Yohimbine and the model anxiety state. J Clin Psych. 1983;45:512–515.
   Google Scholar
• Holmberg G, Gershon S. Autonomic and psychic effects of yohimbine hydrochloride. Psychopharmacol. 1961;2:93–106.
   PubMed Web of Science ®Google Scholar
• Holmberg G, Gershon S, Beck LH. Yohimbine as an autonomic test drug. Nature. 1962;193:1313–1314.
   Google Scholar
• Ingram CG. Some pharmacologic actions of yohimbine and chlorpromazine in man. Clin Pharm Ther. 1962;3:345–352.
   Web of Science ®Google Scholar
• Kearney T, Tu N, Haller C. Adverse drug events associated with yohimbine-containing products: a retrospective review of the California poison control system-reported cases. Ann Pharmacother. 2010;44:1022–1029.
   PubMed Web of Science ®Google Scholar
• Kucio C, Jonderko K, Piskorska D. Does yohimbine act as a slimming drug? Isr J Med Sci. 1991;27:550–556.
   PubMedGoogle Scholar
• Lai MW, Klein-Schwartz W, Rodgers GC, Abrams JY, Haber DA, Bronstein AC, Wruk KM. 2005 Annual report of the American Association of Poison Control Centers’ national poisoning and exposure database. Clin Toxicol. 2006;44:803–932.
   PubMed Web of Science ®Google Scholar
• Lambert GA, Lang WJ. Interaction between yohimbine alkaloids and amphetamine in mice. Psychopharmacology. 1977;51:209–212.
   PubMedGoogle Scholar
• Linden CH, Vellman WP, Rumack B. Yohimbine: a new street drug. Ann Emerg Med. 1985;14:1002–1004.
   PubMed Web of Science ®Google Scholar
• Litovitz TL, Klein-Schwartz W, Rodgers GC Jr, Cobaugh DJ, Youniss J, Omslaer JC, May ME, Woolf AD, Benson BE. 2001 Annual report of the American Association of Poison Control Centers toxic exposure surveillance system. Am J Emerg Med. 2002;20:391–452.
   PubMed Web of Science ®Google Scholar
• McCarty MF. Pre-exercise administration of yohimbine may enhance the efficacy of exercise training as a fat loss strategy by boosting lipolysis. Med Hypothesis. 2002;58:491–495.
   PubMed Web of Science ®Google Scholar
• Ostojic SM. Yohimbine: the effects on body composition and exercise performance in soccer players. Res Sports Med. 2006;14:289–299.
   PubMedGoogle Scholar
• Owen JA, Nakatsu SL, Fenemore J, Condra M, Surridge DHC, Morales A. The pharmacokinetics of yohimbine in man. Eur J Clin Pharmcol. 1987;32:577–582.
   PubMed Web of Science ®Google Scholar
• Pittler MH, Ernst E. Complementary therapies for reducing body weight: a systematic review. Int J Obes (Lond). 2005;29:1030–1038.
   PubMed Web of Science ®Google Scholar
• Richards JK, Simms JA, Bartlett SE. Conditioned cues and yohimbine-induced reinstatement of beer and near-beer seeking in long-Evans rats. Addict Biol. 2008;14:144–151.
   PubMedGoogle Scholar
• Sandler B, Aronson P. Yohimbine-induced cutaneous drug eruption, progressive renal failure, and lupus-like syndrome. Urology. 1993;41:343–345.
   PubMed Web of Science ®Google Scholar
• Sax L. Yohimbine does not affect fat distribution in men. Int J Obesity. 1991;15:561–565.
   PubMed Web of Science ®Google Scholar
• Shannon M, Neuman MI. Yohimbine. Pediatr Emerg Care. 2000;16:49–50.
   PubMed Web of Science ®Google Scholar
• Sun HS, Green TA, Theobald DEH, Birnbaum SG, Graham DL, Zeeb FD, Nestler EJ, Winstanley CA. Yohimbine increases impulsivity through activation of cAMP response element binding in the orbitofrontal cortex. Biol Psych. 2010;67:649–656.
   PubMedGoogle Scholar
• Sunderland TCH, Ngo-Mpeck ML, Tchoundjeu Z, Laird SA. Yohimbe. In: P Shanley, AR Pierce, SA Laird, and A Guillen–(Eds.), Tapping the green market: certification and management of non-timber forest products . (pp. 215–224) London: Earthscan Publication, 2002.
   Google Scholar
• Tam SW, Worcel M, Wyllie M. Yohimbine: a clinical review. Pharmacol Ther. 2001;91:215–243.
   PubMed Web of Science ®Google Scholar
• Varkey S. Overdose of yohimbine. BMJ. 1992;304:548.
   PubMed Web of Science ®Google Scholar
• Vasa RA, Pine DS, Masten CL, Vythilingam M, Collin C, Charney DS, Neumeister A, Mogg K, Bradley BP, Bruck M, Monk CS. Effects of yohimbine and hydrocortisone on panic symptoms, autonomic responses, and attention to threat in healthy adults. Psychopharmacology. 2009;204:445–455.
   PubMed Web of Science ®Google Scholar
• Watson WA, Litovitz TL, Klein-Schwartz W, Rodgers GC Jr, Youniss J, Reid N, Rouse WG, Rembert RS, Borys D. 2003 Annual report of the American Association of Poison Control Centers toxic exposure surveillance system. Am J Emerg Med. 2004;22:335–404.
   PubMed Web of Science ®Google Scholar
• Watson WA, Litovitz TL, Rodgers GC Jr, Klein-Schwartz W, Reid N, Youniss J, Flanagan A, Wruk KM. 2004 Annual report of the American Association of Poison Control Centers toxic exposure surveillance system. Am J Emerg Med. 2005;23:589–666.
   PubMed Web of Science ®Google Scholar
• Watson WA, Litovitz TL, Rodgers GC Jr, Klein-Schwartz W, Youniss J, Rose SR, Borys D, May ME. 2002 Annual report of the American Association of Poison Control Centers toxic exposure surveillance system. Am J Emerg Med. 2003;21:353–421.
   PubMed Web of Science ®Google Scholar
• Woolf AD, Watson WA, Smolinske S, Litovitz T. The severity of toxic reactions to ephedra: comparisons to other botanical products and national trends from 1993–2002. Clin Toxicol. 2005;43:347–355.
   PubMed Web of Science ®Google Scholar
• Zahorska-Markiewicz B, Kucio C, Piskorska D. Adrenergic control of lipolysis and metabolic responses in obesity. Horm Metabol Res. 1986;18:693–697.
   PubMed Web of Science ®Google Scholar